Pricing Log in Create free account

Parabilis Medicines, Inc. (PBLS) vs Tarsus Pharmaceuticals, Inc. (TARS)

Parabilis Medicines, Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Parabilis Medicines, Inc. and Tarsus Pharmaceuticals, Inc. are of similar size ($3.4B and $3.3B). Parabilis Medicines, Inc. has the higher net margin (0.00% vs −102.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Parabilis Medicines, Inc. leads on 8 and Tarsus Pharmaceuticals, Inc. on 4.

Valuation

Metric PBLS TARS Biotechnology median
P/E n/m n/m 10.60
P/S n/m 4.68 9.40
P/B 0.79 30.71 2.13
Price to free cash flow n/m 136.27 25.18
EV/EBITDA 1.67 n/m 0.66
EV/Sales n/m 4.34 9.02
Earnings yield (290.38%) (22.07%) (32.88%)
Free cash flow yield (14.42%) 0.73% (23.13%)

Profitability

Metric PBLS TARS Biotechnology median
Gross margin — 93.21% 68.51%
Operating margin 0.00% (102.04%) 0.00%
Net margin 0.00% (102.93%) 0.00%
Free cash flow margin 0.00% 4.76% 0.00%
Return on equity 0.00% (319.84%) (51.96%)
Return on assets 0.00% (135.04%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PBLS TARS Biotechnology median
Revenue growth (TTM) — 86.34% 6.76%
EPS growth (last fiscal year) (10.69%) 48.21% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric PBLS TARS Biotechnology median
Debt to equity 0.01 0.70 0.00
Current ratio 17.91 1.96 4.97
Net debt to EBITDA 0.09 4.66 1.01

Dividend

Metric PBLS TARS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PBLS TARS Biotechnology median
Market cap 3.44b 3.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack